Novel subtype-selective and weakly desensitizing AMPA receptor partial agonist (Ki values are 44, 109, 223, 1890 and 2090 nM at GluK1, GluA1, GluA2, GluA3 and GluA4 receptors respectively). Exhibits potent agonist activity at GluA1 and GluA2 subunit-containing AMPA receptors (EC50 values are 24.9 and 13.9 μM respectively) and is excitotoxic in vitro.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 239.23. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||8.36 mL||41.8 mL||83.6 mL|
|2.5 mM||1.67 mL||8.36 mL||16.72 mL|
|5 mM||0.84 mL||4.18 mL||8.36 mL|
|25 mM||0.17 mL||0.84 mL||1.67 mL|
References are publications that support the biological activity of the product.
Butini et al (2008) 1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptor ligands. Structure-activity relationships and identification of potent and selective iGluR5 modulators. J.Med.Chem. 51 6614 PMID: 18811139
Campiani et al (2001) Characterization of the 1H-cyclopentapyrimidine-2,4(1H,3H)-dione derivative (S)-CPW399 as a novel, potent and subtype-selective AMPA receptor full agonist with partial desensitization properties. J.Med.Chem. 44 4501 PMID: 11741469
Sinclair et al (2003) Inherent desensitisation-preventing properties of a novel subtype-selective AMPA receptor agonist, (S)-CPW 399, as a possible explanation for its excitotoxic action in cultured cerebellar granule cells. Neurochem.Int. 42 499 PMID: 12547649
If you know of a relevant reference for (S)-CPW 399, please let us know.
View Related Products by Product Action
Keywords: (S)-CPW 399, (S)-CPW 399 supplier, Subtype-selective, weakly, desensitizing, AMPA, agonists, Glutamate, Receptors, iGlur, Ionotropic, (S)-CPW399, 1543, Tocris Bioscience
Citations for (S)-CPW 399
Citations are publications that use Tocris products.
Currently there are no citations for (S)-CPW 399. Do you know of a great paper that uses (S)-CPW 399 from Tocris? Please let us know.
Reviews for (S)-CPW 399
There are currently no reviews for this product. Be the first to review (S)-CPW 399 and earn rewards!
Have you used (S)-CPW 399?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.